R&D News | pharmaphorum

News

Last year’s UK biotech financing dip extends into 2023

The first quarter of 2023 saw just £295 million raised by UK-based life sciences and biotech companies, signalling that investor confidence remains low after a disappointi

News

Vedanta scores $106.5m to take microbiome drug into ph3

In the face of a challenging biotech financing environment, Vedanta Bio has ra

News

Lilly goes toe-to-toe with Novo Nordisk on obesity

Eli Lilly has raised the stakes in its looming battle with Novo Nordisk in the market for obesity drugs, planning a clinical trial that will directly compare its new thera

News

Novartis cuts 10% of R&D projects in ‘focused’ strategy

Novartis revealed this morning that it has decided to trim back its R&D pipeline by around 10% to 136 projects, as it continues its transition into a pure-play innovat

News

AZ, Ionis hail phase 3 data for ATTR drug eplontersen

AstraZeneca have broken out the data they teased last month for transthyretin amyloidosis (ATTR) therapy eplontersen, showing that the drug was effective at slowing down d

News

When can single-arm trials support drug filings?

The EMA has launched a consultation on the circumstances in which single-arm trials (SATs) – those without a control group – can be used to support marketing applications

Last year’s UK biotech financing dip extends into 2023

Vedanta scores $106.5m to take microbiome drug into ph3

Lilly goes toe-to-toe with Novo Nordisk on obesity

Novartis cuts 10% of R&D projects in ‘focused’ strategy

AZ, Ionis hail phase 3 data for ATTR drug eplontersen

When can single-arm trials support drug filings?

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks